BioMarin acquires Amicus Therapeutics for $4.8bn [Yahoo! Finance]
BioMarin Pharmaceutical Inc. (BMRN)
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.biomarin.com
Company Research
Source: Yahoo! Finance
The deal was originally announced in December 2025. With the acquisition, BioMarin adds two new treatments for lysosomal storage diseases, Galafold (migalastat) for Fabry disease, and Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat) for Pompe disease. The company also secures US rights to DMX-200, an oral investigational small molecule for focal segmental glomerulosclerosis (FSGS), currently in Phase III trials. BioMarin president and CEO Alexander Hardy said: “The completion of the Amicus acquisition advances BioMarin's strategy to strengthen and diversify our growth profile while furthering our mission to deliver medicines for people living with rare diseases. “BioMarin's global scale, established commercial infrastructure, and advanced in-house manufacturing capabilities build on Amicus' legacy and position us to bring Galafold and Pombiliti+Opfolda to more patients around the world.” Supplied as a 123mg capsule, Galafold is an oral pharmacological chaperone o
Show less
Read more
Impact Snapshot
Event Time:
BMRN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMRN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMRN alerts
High impacting BioMarin Pharmaceutical Inc. news events
Weekly update
A roundup of the hottest topics
BMRN
News
- BioMarin Pharmaceutical (BMRN) is now covered by Morgan Stanley. They set an "overweight" rating and a $120.00 price target on the stock.MarketBeat
- BioMarin Completes Acquisition of Amicus Therapeutics [Yahoo! Finance]Yahoo! Finance
- BioMarin Completes Acquisition of Amicus Therapeutics [TheStreet.com]TheStreet.com
- BioMarin Completes Acquisition of Amicus TherapeuticsPR Newswire
- BioMarin to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, May 4, 2026, at 4:30pm ET [TheStreet.com]TheStreet.com
BMRN
Earnings
- 2/23/26 - Beat
BMRN
Sec Filings
- 4/29/26 - Form SCHEDULE
- 4/27/26 - Form 8-K
- 4/23/26 - Form 8-K
- BMRN's page on the SEC website